Alcon (ALC) Q2 FY25 earnings call

Earnings call· Jun 2025 (Q2 FY25)· Health Care· Aug 20, 2025

Source: earnings call transcript

Alcon navigated a softer surgical market in Q2 FY25, particularly impacting revenue, leading to a revised full-year sales outlook. Despite near-term headwinds, the company made significant strategic moves with the acquisitions of STAAR Surgical and LumiThera, alongside successful launches of key products like Unity VCS, PanOptix Pro, and Tryptyr, positioning it for accelerated growth in the second half and beyond. Management remains confident in long-term market fundamentals and operational leverage.

You’re reading a preview. Opening the full call uses 1 concall credit.

ALC operating KPIs by quarter

ALC operating KPIs stated on its earnings calls, by fiscal quarter
KPI	This call Jun 2025 Q2 FY25	Sep 2025 Q3 FY25	Change vs prior quarter
Installed base Consoles	30K We've got 30,000 consoles out there. Source: earnings call transcript	30K We have a 30% or so -- or sorry, a 30,000 unit base that you stretch out over 10 years and you kind of come up with an average, and it's obviously a little more delayed in the back end and a little faster in the front end. Source: earnings call transcript	0%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.